Figure 2.
Rosiglitazone treatment delays thyroid cancer progression and blocks metastasis of ThrbPV/PV mice. (A). Rosiglitazone treatment decreases tumor growth (open bar) as compared with untreated mice (closed bar). (B). Rosiglitazone treatment induces apoptosis of tumor cells. Representative H&E stained sections of thyroid of treated (panels b and d) or untreated (panels a and c) ThrbPV/PV mice are shown. The hyperplastic thyroids in untreated mice show extensive hyperplasia of follicular epithelia, shown at low (panel a) and high (panel c) magnification. Similar fields from mice treated with rosiglitazone show epithelial cellular damage, including cell and nuclear swelling (arrowhead, panel d) and nuclear chromatin condensation typical of apoptotic cell death (arrows, panel d). (Mags: panels a, b = ×75; panels c, d= ×300). (C). Rosiglitazone treatment decreases occurrence of capsular invasion, vascular invasion, and metastasis in ThrbPV/PV mice. “*” denotes that p values could not be calculated since no metastasis was observed in drug-treated mice [39].